aibioHumacyte securities suit over Symvess safety enters discovery; four derivative suits pending
Tickers HUMA
The North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal.
Key facts
- Company
- Humacyte, Inc. (NASDAQ: HUMA)
- News type
- Legal
- Primary source
- Humacyte 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Humacyte, Inc. (Nasdaq: HUMA) said in its 10-Q filed August 12, 2026 that discovery began on June 4, 2026 in a securities class action over statements about its product Symvess. James A. Cutshall filed Cutshall v. Humacyte, Inc., et al., No. 1:24-cv-00954, on November 18, 2024 in the U.S. District Court for the Middle District of North Carolina.
The suit names Humacyte and certain of its officers, and the 10-Q does not identify them. Humacyte's 10-K signed March 31, 2025 shows Laura E. Niklason, M.D., Ph.D., as president and chief executive officer and Dale A. Sander as chief financial officer. Neither filing says they are defendants. Separate derivative suits on Humacyte's behalf name current or former directors and officers, and in two cases Ayabudge LLC. The claims described here are allegations.
The case
The initial complaint covered buyers of Humacyte securities between May 10, 2024 and October 17, 2024. It asserts claims under Sections 10(b) and 20(a) of the Exchange Act. It alleges false or misleading statements and omissions about the biologics license application for the vascular trauma indication and about deficiencies at the company's Durham, North Carolina manufacturing facility. It seeks unspecified compensatory damages, attorneys' fees and costs.
The court appointed co-lead plaintiffs on January 31, 2025. Their amended complaint, filed May 22, 2025, widens the class period to August 14, 2023 through March 25, 2025. It adds allegations about the safety of Symvess and about Humacyte's financial condition and liquidity.
Defendants
In the class action, the defendants are Humacyte and the unnamed officers. In the derivative suits, the case captions name Sebelius (Silva v. Sebelius, No. 1:25-cv-00005), Niklason (Misko v. Niklason, No. 1:25-cv-00028, and Olson v. Niklason, No. 1:25-cv-00123) and Bamforth (Heller v. Bamforth, No. 1:25-cv-00604, and Dusci v. Bamforth, No. 1:25-cv-00722). Silva and Misko also name Ayabudge LLC.
The 10-Q does not list the other individual defendants. The 10-K signed March 31, 2025 lists these directors: Niklason, Kathleen Sebelius, John Bamforth, Emery N. Brown, Michael T. Constantino, Brady W. Dougan, C. Bruce Green, Keith Anthony Jones, Todd M. Pope, Diane Seimetz, Max Wallace and Susan Windham-Bannister. The filings do not say which of them, beyond the names in the case captions, are defendants.
Where it stands
Defendants moved to dismiss the amended complaint on July 25, 2025. On March 31, 2026 the court partly granted and partly denied the motion. It dismissed the claims about financial condition, liquidity and manufacturing facility deficiencies without prejudice, and it sustained the product safety claims at the pleading stage.
Silva and Misko, filed January 7 and 10, 2025 in the Middle District of North Carolina, were consolidated on February 18, 2025. They assert Section 14(a) and fiduciary duty claims, among others, and Misko adds a contribution claim under Sections 10(b) and 21(d). Olson was filed February 19, 2025 after a December 19, 2024 demand letter and alleges the company refused the demand. The board formed a demand evaluation committee on January 24, 2025. Dusci was filed June 9, 2025 in the District of Delaware. Heller was filed June 26, 2026, after a May 19, 2025 demand letter on which the board deferred action until the motion to dismiss was resolved. The court has granted joint motions to stay Olson, Heller and Dusci. The motion is pending in the consolidated action.
Why it matters to shareholders
Humacyte disputes all claims in the class action and disputes that the plaintiffs in the consolidated, Dusci and Olson derivative actions have standing to sue on its behalf. It says it cannot estimate a loss or range of loss, which could be material, and it has accrued no material liability because it deems a negative outcome not probable. The 10-Q adds that associated costs could materially affect its results.
The company has agreed to indemnify directors and officers to the extent Delaware law permits. It carries directors and officers insurance meant to reduce its exposure, and reports no costs so far under the indemnification obligations.